Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
Baxter
McKinsey
AstraZeneca

Last Updated: August 19, 2022

Investigational Drug Information for Afuresertib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Afuresertib?

Afuresertib is an investigational drug.

There have been 14 clinical trials for Afuresertib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 9th 2020.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Endometrial Neoplasms. The leading clinical trial sponsors are Laekna Limited, GlaxoSmithKline, and Novartis Pharmaceuticals.

There are fifty-eight US patents protecting this investigational drug and six hundred and thirty-three international patents.

Recent Clinical Trials for Afuresertib
TitleSponsorPhase
Human Mass Balance and Biotransformation Study of [14C]AfuresertibLaekna LimitedPhase 1
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1Laekna LimitedPhase 1/Phase 2
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast CancerLaekna LLCPhase 1

See all Afuresertib clinical trials

Clinical Trial Summary for Afuresertib

Top disease conditions for Afuresertib
Top clinical trial sponsors for Afuresertib

See all Afuresertib clinical trials

US Patents for Afuresertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Afuresertib See Plans and Pricing Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) See Plans and Pricing
Afuresertib See Plans and Pricing .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof Quadriga Biosciences, Inc. (Los Altos, CA) See Plans and Pricing
Afuresertib See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Afuresertib See Plans and Pricing Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population UNITY BIOTECHNOLOGY, INC. (Brisbane, CA) BUCK INSTITUE FOR RESEARCH ON AGING (Novato, CA) MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (Rochester, MN) See Plans and Pricing
Afuresertib See Plans and Pricing Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways Asana BioSciences, LLC (Lawrenceville, NJ) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Afuresertib

Drugname Country Document Number Estimated Expiration Related US Patent
Afuresertib Australia AU2015211021 2034-01-28 See Plans and Pricing
Afuresertib Australia AU2020244600 2034-01-28 See Plans and Pricing
Afuresertib Brazil BR112016017564 2034-01-28 See Plans and Pricing
Afuresertib Canada CA2939121 2034-01-28 See Plans and Pricing
Afuresertib Canada CA3100140 2034-01-28 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
Baxter
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.